BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Income Statement
USA - NASDAQ:BDTX - US09203E1055 - Common Stock
3.82 USD
0 (0%)
3.81 USD
-0.01 (-0.26%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 70.00M | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 65.30M | 78.78M | 86.46M | 92.83M | 126.87M | |||
| Research and Development | 45.04M | 51.31M | 59.35M | 64.44M | 96.83M | |||
| Selling, General, and Administrative Expenses | 20.26M | 27.47M | 27.11M | 28.39M | 30.04M | |||
| Operating Income | 4.71M | -78.78M | -86.46M | -92.83M | -126.87M | |||
| Interest Income/Expense | 2.79M | 2.18M | 1.92M | -220.00K | 3.46M | |||
| Other Income/Expense | 6.94M | 6.92M | 2.09M | -350.00K | -2.19M | |||
| Non Recurring Items | N/A | N/A | N/A | N/A | N/A | |||
| Income Before Taxes | 14.44M | -69.68M | -82.44M | -91.17M | -125.60M | |||
| Income Tax | N/A | 0.00 | N/A | N/A | N/A | |||
| Net Income | 14.44M | -69.68M | -82.44M | -91.17M | -125.60M | |||
| EBITDA | 5.05M | -78.44M | -86.02M | -92.32M | -126.66M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | 0.24 | -1.27 | -1.88 | -2.51 | -3.47 | |||
| Non GAAP EPS | 0.23 | -1.27 | -1.88 | -2.52 | -3.47 | |||
| Statistics | ||||||||
| Profit Margin | 20.63% | N/A | N/A | N/A | N/A | |||
| Operating Profit Margin | 6.72% | N/A | N/A | N/A | N/A | |||
All data in USD